> Recombinetics

Gene-editing Solutions

Delivering viable products and generating revenues today, Recombinetics (RCI) is rapidly growing to broadly commercialize the sale and distribution of its gene-edited animals.

RCI far outpaces its competitors in intellectual property with a global patent portfolio of 33 issued US patents, more than 200 additional applications filed, and first-use and enabling patents for livestock for both CRISPR and TALENs gene-editing technologies.

Recombinetics aims to provide gene-editing solutions for some of the world’s most intractable challenges, from improving human health to sustainably feeding an ever-growing population.

Founded in 2008, RCI is widely recognized as the global thought leader in livestock gene editing and applied technology.

RCI has developed a proprietary DNA toolkit for use in biomedical research, regenerative medicine, and agriculture through its subsidiaries Acceligen, Regenevida, and Surrogen.

PRECISION BREEDING FOR HEALTHY, SAFE, ABUNDANT FOOD

RCI’s agriculture and aquaculture subsidiary, Acceligen leverages RCI’s DNA toolkit and expertise to develop precision breeding solutions for healthier food animals raised more humanely and sustainably. Precision breeding benefits animals, producers, retailers, consumers, and the environment.

Acceligen delivers high-value, naturally occurring traits in elite livestock and aquaculture populations to achieve genetic progress in a single generation.

For farmers and genetics companies seeking animal health and welfare improvements, this provides a complementary and safe approach to conventional breeding—which can be difficult, time-intensive, and cost-prohibitive.

PIG MODELS OF HUMAN DISEASES

RCI’s disease model subsidiary, Surrogen, leverages RCI’s DNA toolkit and expertise to develop custom-tailored pig models that simulate the onset and progression of human disease.

These models enable more efficient and effective basic, preclinical, and transplant research which accelerate the conversion of science to medical solutions.

Surrogen is currently developing pig models in these focus areas: cancer, cardiovascular, congenital/heredity/neonatal, diabetes/metabolic syndrome, and neurodegenerative.

HUMAN CELLS, TISSUES & ORGANS GROWN INSIDE OF OINKUBATORS

RCI’s regenerative medicine subsidiary, Regenevida, leverage RCI’s DNA toolkit and expertise, including advances gained through Surrogen, to develop pigs as production systems for cultivating cells, tissues, and ultimately organs for human therapeutic applications.

Regenevida’s creation of identical replicas of a patient’s own organs with their own DNA, has the potential to transform the face of modern medicine, drastically improve the quality-of-life for millions and redefine what is considered “possible” in medicine.

Recombinetics

www.recombinetics.com
+1-612-727-2000
[email protected]
3388 Mike Collins Dr., # A Eagan, MN 55121

Submit your Innovation Story

Join and network with a global community of innovators  by sharing your success story with the world.

INNOVATE®

NEWSLETTER

Our promise: we dislike spam as much as the next person, and promise never to break your trust in us. We will never sell data – this is only used for the INNOVATE® Newsletter

GLOBAL INSIGHT

GLOBAL INNOVATION

FOR TODAYS BIG THINKERS